Evaxion AS Stock Price, News & Analysis

Evaxion (NASDAQ: EVAX) announced it will present two-year clinical efficacy data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma, at the ESMO Congress 2025 in Berlin. The trial combines EVX-01 with MSD's KEYTRUDA® and has shown promising results, with interim one-year data demonstrating a 69% Overall Response Rate and tumor reduction in 15 out of 16 patients.

The presentation will take place on October 17, 2025, featuring data that validates their AI-Immunology™ platform's predictions, which showed significant correlation (p=0.00013) with immune responses to the personalized vaccine's neoantigens. Each patient in the trial received a unique vaccine designed based on their individual biology.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has finalized a significant debt-to-equity conversion agreement with the European Investment Bank (EIB). Under the agreement, EIB will convert €3.5 million of its existing €7 million loan into equity through warrant purchases at $4.87 per share, representing an 89% premium to the previous day's closing price.

The strategic transaction immediately strengthens Evaxion's equity position by $4.1 million (€3.5 million), while significantly reducing the company's debt burden. This restructuring is expected to enhance Evaxion's financial flexibility and improve cash flow, marking a positive development in the company's financial management strategy.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced significant changes to its executive management team. CEO Christian Kanstrup has stepped down, with Chief Scientific Officer Dr. Birgitte Rønø appointed as interim CEO while the company searches for a permanent replacement.

The company has also appointed Thomas Schmidt as permanent Chief Financial Officer, following his interim role since November 2024. These management changes are part of Evaxion's strategy to optimize value from its proprietary AI-Immunology™ platform and pipeline developed over 17 years.

The Board of Directors is conducting a search for a new permanent CEO with strong business development focus, proven transformational leadership, and strategic partnership capabilities. Dr. Rønø, who has been with Evaxion since 2017 and joined Executive Management in 2021, will ensure leadership continuity during the transition period.

Evaxion (NASDAQ: EVAX) has announced the addition of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS) to its R&D pipeline. Initial computational analysis shows that the company's AI-Immunology™ platform can successfully identify novel vaccine targets to combat GAS, which affects hundreds of millions globally each year.

The bacteria can cause severe complications including rheumatic heart disease, necrotizing fasciitis, strep throat, and scarlet fever. The development of EVX-B4 represents a significant milestone in Evaxion's 2025 objectives, bringing their pipeline to eight vaccine candidates - five for infectious diseases and three for cancer.

Evaxion (NASDAQ: EVAX) has received a grant from the Gates Foundation to develop a new polio vaccine using its AI-Immunology™ platform. The project aims to help eradicate polio globally by designing a novel vaccine construct that eliminates the need for live viruses in production. Despite existing vaccines, polio remains a threat with potential for global resurgence. Evaxion's AI platform will identify and combine various antigens to combat the virus, creating new antigen constructs for selection and validation. CEO Christian Kanstrup highlighted that the grant enables platform validation without additional operational costs. The innovative approach seeks to overcome limitations of current vaccines, which use inactivated or attenuated viruses, by developing a safer and more effective alternative.

Evaxion (NASDAQ: EVAX) reported Q1 2025 financial results and provided business updates. Key highlights include: EVX-01 phase 2 trial progression with 80% of vaccine targets triggering tumor-specific immune responses, significantly higher than comparable vaccines. The company's cash position improved to $17.8 million as of March 31, 2025, from $6.0 million in December 2024, extending runway to mid-2026. Q1 2025 showed a net loss of $1.6 million ($0.01 per share) compared to net income of $1.2 million in Q1 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year. The company expects potential value catalysts in H2 2025, including EVX-01 two-year data readout and possible MSD option exercise for EVX-B2 and EVX-B3 programs. Evaxion is targeting at least two new partnership agreements in 2025, though market conditions may impact timing.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q1 2025 financial results announcement and business update for May 27, 2025, before Nasdaq CM market opening. The company's management will host a conference call and webcast at 14:30 CET/08:30 EST on the same day. Investors and the public can participate in the event by registering in advance to receive dial-in details and a PIN code. The presentation will be followed by a Q&A session, and a recording will be made available on Evaxion's website after the event.

Evaxion (NASDAQ: EVAX) has initiated a one-year extension of its Phase 2 trial for EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma. The first patient has received treatment in this extension phase, which will evaluate EVX-01 as a monotherapy following its initial two-year combination with checkpoint inhibitors. The extension aims to assess long-term benefits with minimal additional costs. The original Phase 2 trial has shown promising results, with 69% Overall Response Rate and tumor reduction in 15 out of 16 patients at the one-year mark. Notably, 80% of EVX-01's vaccine targets successfully triggered immune responses. The trial extension will provide insights into treatment durability for up to three years, with two-year data expected in H2 2025.

Evaxion Biotech (NASDAQ: EVAX) has presented compelling new data for its personalized cancer vaccine EVX-01 at the AACR Annual Meeting. The vaccine, designed using AI-Immunology™ platform, demonstrated an impressive 80% tumor-specific immune response rate among vaccine targets, surpassing previously reported rates of 71% and 79% at ASCO and ESMO 2024 meetings.

The ongoing phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® for advanced melanoma treatment. The immune response data shows strong and sustained results, with enhanced effects from booster immunizations. The trial, which previously showed strong one-year interim clinical data, is progressing toward its two-year data readout in H2 2025 and has been extended for a third year for comprehensive assessment.